| NS3 Inhibitor |
Development Phase |
Genotype |
Company |
Nature |
| SCH 503034 (Boceprevir) |
FDA Approved |
1 ,2,5,6 |
Merck |
Linear peptidomimetic |
| VX-950 (Telaprevir) |
FDA Approved |
1 ,2,5,6 |
Vertex Pharmaceuticals |
Linear peptidomimetic |
| BI 201335 |
Phase III |
1 |
Boehringer Ingelheim |
Linear tripeptide |
| SCH 900518 (Narlaprevir) |
Phase II |
1 |
Merck & Co |
Linear ketoamide |
| SCH6 (SCH446211) |
On hold |
2 |
Merck & Co |
Ketoamide peptidomimetic |
| BILN 2061 (Ciluprevir) |
Trial stopped |
1 |
Boehringer Ingelheim |
Macrocyclic |
| TMC435 (Simeprevir) |
Phase III |
1 ,2,5,6 |
(Medivir / Tibotec) |
Macrocyclic |
| ITMN-191/RG7227 (Danoprevir) |
Phase II |
1 |
InterMune/Roche |
Macrocyclic |
| MK-7009 (Vaniprevir) |
Phase II |
1 |
Merck & Co |
Macrocyclic |
| GS-9256 |
Phase II |
1 |
Gilead |
Macrocyclic |
| ACH-1625 |
Phase II |
1 |
Achillion |
Macrocyclic |
| MK-5172 |
Phase II |
1,2 |
Merck & Co |
Macrocyclic |
| ABT-450 |
Phase II |
1 |
Abbott/Novartis |
Macrocyclic |
| IDX320 |
Phase II |
1, 1b, 2a, 3a and 4a |
Idenix |
Macrocyclic |
| BMS-650032 (Asunaprevir) |
Phase II |
1,4 |
Bristol-Myers Squibb |
Macrocyclic |
| ACH-806 (GS-9132) |
Phase II |
1 |
Achillion and Gilead |
N/A |
| PHX1766 |
Phase I |
1 |
Phenomix |
N/A |
|